Company Overview and News

BRIEF-Crius Energy Will Seek Unitholder Approval Of Amendments Proposed By JCP Investment Management

2018-04-19 reuters
Upvote Downvote

Crius to Put Forward Governance Amendments for Unitholder Approval at Annual General Meeting 

2018-04-19 globenewswire
TORONTO, April 19, 2018 (GLOBE NEWSWIRE) -- Crius Energy Trust (TSX:KWH.UN) (the "Trust", "Crius" or the "Company") today announced that it will seek unitholder approval of certain governance amendments proposed by dissident unitholder JCP Investment Management, LLC (“JCP”). Unitholders will have the opportunity to vote on the amendments at Crius’ Annual General Meeting (“AGM”) on May 29, 2018.
Upvote Downvote

BRIEF-Crius Announces TSX Approval Of Normal Course Issuer Bid

2018-03-27 reuters
Upvote Downvote

Controversial Monthly Payer Yields 11%, Big Q4 '17 Earnings, No K-1, Goes Ex This Week

2018-03-25 seekingalpha
These trust units have tanked in 2018 due to a short seller hit piece. But this has created a buying opportunity.
Upvote Downvote

Crius Energy Trust 2017 Q4 - Results - Earnings Call Slides

2018-03-12 seekingalpha
The following slide deck was published by Crius Energy Trust in conjunction with their 2017 Q4 earnings call.
Upvote Downvote

BRIEF-Crius Energy Trust Q4 ‍Revenue $248.5 Million

2018-03-09 reuters
* CRIUS ENERGY TRUST - REVENUE OF $248.5 MILLION IN Q4 OF 2017, REPRESENTING AN INCREASE OF 45.0% FROM $171.4 MILLION IN Q4 OF 2016 Source text for Eikon: Further company coverage:
Upvote Downvote

Dividend Sensei's Portfolio Update 25: Invest Against The Crowd If You Want To Get Rich

2018-03-06 seekingalpha
Another hard week for high-yield stocks especially: REITs, MLPs, and utilities created even more amazing buying opportunities.
Upvote Downvote

TheBaron VI: Active February Brings New Strategy

2018-03-06 seekingalpha
As the portfolio grows I have begun to modify my investment criteria to initiate new holdings within low and medium yield companies to complement my high yield holdings.
Upvote Downvote

Crius Energy Trust: The Risks Are Overblown

2018-03-02 seekingalpha
Crius sold off markedly after a short selling article was published on Seeking Alpha on February 28, 2018.
Upvote Downvote

Crius Energy Trust: An Unsustainable Collision Course

2018-02-28 seekingalpha
Crius' non-IFRS “Payout Ratio” includes multiple questionable adjustments which have given investors a false sense of security. We think Crius is on the precipice of failure.
Upvote Downvote

Dividend Sensei's Portfolio Update 24: No Dividend Is Ever Truly Safe

2018-02-27 seekingalpha
It was an eventful week to say the least, with a combination of high volatility for dividend stocks, and some very big earnings news.
Upvote Downvote

Dividend Sensei's Portfolio Update 23: Hunkering Down In Case Market Meltdown Is Just Getting Started

2018-02-20 seekingalpha
Thanks to the correction the last two weeks was the busiest buying time for me in months.
Upvote Downvote

TheBaron Investing: Marijuana Collapses

2018-02-05 seekingalpha
The market has decided to cool on marijuana companies, which is appropriate but frustrating to see an undervalued company decline.
Upvote Downvote

Crius Energy Trust - Destroying Value One Acquisition At A Time

2018-01-23 seekingalpha
Founded in 2012, Crius Energy Trust (OTC:CRIUF) is a US energy marketing firm listed on the TSX. They provide electricity and natural gas solutions to both residential and commercial customers. Although some may describe the firm as a utility, I do not think that is appropriate given their almost complete lack of physical assets (PP&E represents less than 1.5% of their total assets). Similar to a utility the firm pays a rather large dividend, c.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...